Wingwomen and HeraMED Announce Doula Led Initiative for Patients at-risk for Preeclampsia and Gestational Hypertension
Boston, Massachusetts – Wingwomen, a Boston-based FemHealth startup, is thrilled to announce its collaboration with HeraMED Limited (ASX:HMD), a leader in medical data and technology, for a groundbreaking Doula Led 90-day Cardiovascular evaluation initiative for pregnant patients during their third and fourth trimesters. The initiative is set to commence in January 2024.
As part of the initiative, The Wingwomen will provide access to 10-12 Doulas, cardiovascular educators, and nutritional health coaches to eligible low risk patients in California and Massachusetts. The Doulas will provide additional education throughout the third and fourth trimester’s around risks associated with preeclampsia, gestational diabetes and gestational hypertension.
HeraMED will supply up to 10-12 units each of the clinically validated in-home fetal and maternal heart rate monitor “HeraBEAT” monitor, connected Blood Pressure Cuffs, and connected Scales, enabling patients to monitor fetal heart rate, blood pressure, mood, and BMI. The evaluation will focus on user experience, clinical outcomes, satisfaction, and billing codes for patients at risk of Preeclampsia or Gestational Hypertension.
Both companies are united in their mission to revolutionize patient support by employing innovative technology to assist those at risk of preeclampsia, gestational diabetes, and gestational hypertension, under the vigilant guidance of doulas. Moreover, they aim to harness this technology to potentially save lives or expedite responses for at-risk patients experiencing unexpected rises in blood pressure during the critical third and fourth trimesters.
HeraMED President North America, Keith Koby, expressed excitement about the partnership, stating, "Wingwomen represents an excellent partner for HeraMED. I am delighted to be partnering with them as we work towards leading the digital transformation of maternity care."
Wingwomen Founder and CEO, Adonica Shaw, highlighted the importance of embracing technology to improve maternity care. "Wingwomen is embracing thisone-of-a-kind technology to improve maternity care, and I am excited to work with HeraMED as we strive to lead the digital transformation of maternity care."
About Wingwomen:
Wingwomen is a FemHealth startup based in Boston, Massachusetts, offering nonclinical virtual and in-person health coaching, doula support, and clinical services. The company's mission is to improve reproductive health outcomes, reduce time to diagnosis for conditions like Endometriosis and Polycystic Ovary Syndrome, and address knowledge and care gaps in patient populations.
About HeraMED Limited (ASX:HMD):
HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.
The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.
HeraMED Limited ACN 626 295 314
For media inquiries, please contact Alexis at hello@mywingwomen.com